INDIA, September 15, 2023/EINPresswire.com/ — The gene editing market is projected to grow from USD 5.3 billion in 2023 to USD 10.6 billion by 2028 at a CAGR of 15.0%. Rising government funding and number of genomics projects has emerged as a high impact driver for the market. In March 2022, the US National Institutes of Health (NIH) expanded its funding for gene editing research, allocating USD 89 million for additional projects. Similarly, the European Union launched the Horizon 2020 program, providing substantial financial resources to promote genomics research and gene editing projects. Moreover, several countries, including China, Japan, and South Korea, have established national genomics programs and dedicated funding to drive advancements in gene editing technologies.

Get a FREE Sample Report at https://www.reportsnreports.com/contacts/requestsample.aspx?name=7358268

“Gene editing services to witness the highest growth during the forecast period.”

Based on product & service, the gene editing market is segmented into reagents & consumables, software & systems, and services. The gene editing services market includes sequencing services; data analysis; bioinformatics services; and other services, such as informatics, cleanup, gene expression, and DNA synthesis services. Additionally, service providers also offer customized sequencing services. The introduction of sequencing services in biomedical applications is expected to boost the demand for genomic sequencing, subsequently boosting the gene editing market.

“Pharmaceutical & biotechnology companies accounted for the largest share of the global gene editing market in 2022.”

Based on end users, the gene editing market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, and other end users. Other end users include diagnostic companies, CROs, and CDMOs. High demand for gene editing in pharma applications such as pharmacogenomics has contributed to the dominance of this segment throughout the forecast period. The growing importance of biomarkers is expected to drive the use of genomic systems and services in this segment, owing to the various applications of biomarkers in drug development. With this, biotechnology companies are also building genomic databases to discover and develop new therapeutics.

“Asia Pacific is estimated to register the highest CAGR during the forecast period.”

The gene editing market is segmented into North America, Europe, the Asia Pacific (APAC), Latin America, and the Middle East & Africa (MEA). The Asia Pacific region is expected to be the fastest-growing market for gene editing due to the increasing investments in research and the rising applications of gene synthesis for the genetic engineering of cells and tissues of organisms.Cancer has become one of the leading causes of death in Japan, prompting the government to undertake various initiatives to reduce its prevalence and mortality. For example, the Agency for Medical Research and Development has undertaken many research projects, including the Japan Regenerative Medicine Project, Japan Genomic Medicine Project, and Japan Cancer Research Project. The market in Japan has also witnessed various collaborations and partnerships between local organizations and leading global players seeking to introduce and offer technologically advanced products and services in the country.

Breakdown of supply-side primary interviews, by company type, designation, and region:

By Respondent: Supply Side(70%), Demand side(30%)
By Designation: C-level (55%), Director-level (20%), and Others (25%)
By Region: North America (50%), Europe (20%), AsiaPacific(20%), and Rest of the World(10%)
List of Companies Profiled in the Report

Merck KGaA (Germany)
Thermo Fisher Scientific, Inc. (US)
GenScript (China)
Agilent Technologies (US)
PerkinElmer (US)
Lonza (Switzerland)
Tecan Life Sciences (Switzerland)
Sangamo Therapeutics (US)
Editas Medicine (US)
CRISPR Therapeutics AG (Switzerland)
Precision Biosciences (US)
Cellectis S.A. (France)
Intellia Therapeutics (US)
Bluebird Bio, Inc. (US)
Regeneron Pharmaceuticals (US)
AMSBIO (England)
Creative Biogene (US)
Synthego Corporation (US)
Beam Therapeutics Inc. (US)
Caribou Biosciences, Inc. (US)
OriGene Technologies (US)
New England Biolabs (US)
Inscripta (US)
Mammoth Biosciences (US).

Direct Purchase of the Global Gene Editing Market Research Report at https://www.reportsnreports.com/purchase.aspx?name=7358268

Research Coverage:

This report studies the gene editing market based on product & service, technology, application, end user, and region. The report also analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total gene editing market. The report forecasts the revenue of the market segments with respect to five major regions.

Ganesh Pardeshi
ReportsnReports
+1 347-333-3771
ganesh.pardeshi@reportsandreports.com